Sign up to save your podcasts
Or
Share S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was joined by Guiseppe Curigliano, MD, PhD, a full professor of medical oncology at the University of Milan, as well as the director of the Early Drug Development Division and co-chair for the Experimental Therapeutics Program at the European Institute of Oncology in Italy.
In this exclusive interview, Drs Park and Curigliano discussed the potential future role of artificial intelligence across oncology disciplines; how advances in precision medicine will help improve patient care; the significance of seeing early research with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) evolve into the present era, where the agent is FDA approved for the treatment of patients with HER2-positive solid tumors. They also discussed their insights on data from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating T-DXd in patients with HER2-low or -ultralow, hormone receptor–positive, metastatic breast cancer.
View all episodes
By OncLive® On Air
4.2
2121 ratings
In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was joined by Guiseppe Curigliano, MD, PhD, a full professor of medical oncology at the University of Milan, as well as the director of the Early Drug Development Division and co-chair for the Experimental Therapeutics Program at the European Institute of Oncology in Italy.
In this exclusive interview, Drs Park and Curigliano discussed the potential future role of artificial intelligence across oncology disciplines; how advances in precision medicine will help improve patient care; the significance of seeing early research with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) evolve into the present era, where the agent is FDA approved for the treatment of patients with HER2-positive solid tumors. They also discussed their insights on data from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating T-DXd in patients with HER2-low or -ultralow, hormone receptor–positive, metastatic breast cancer.
More shows like OncLive® On Air
View all
Wait Wait... Don't Tell Me!
38,713 Listeners
Marketplace Morning Report
904 Listeners
Marketplace
8,682 Listeners
Research To Practice | Oncology Videos
113 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
JAMA Clinical Reviews
496 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,336 Listeners
OncoPharm
185 Listeners
ASCO Guidelines
43 Listeners
Lung Cancer Considered
27 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
169 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners
NEJM AI Grand Rounds
54 Listeners